Clinical Trial Update: A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Tislelizumab as monotherapy in relapsed or refractory classical Hodgkin lymphoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-10-12